Evaluation of ERα, PR and ERβ isoforms in neoadjuvant treated breast cancer

Oncology Reports

Volumn 24, Issue 3, 2010, Pages 653-659

  Wurster, Martin ^a   Ruoff, Alexandra ^a   Meisner, Christoph ^b   Seeger, Harald ^a   Vogel, Ulrich ^a   Juhasz Böss, Ingolf ^c   Solomayer, Erich ^c   Wallwiener, Diethelm ^a   Fehm, Tanja ^a   Neubauer, Hans ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c SAARLAND UNIVERSITY   (Germany)

Author keywords

Breast cancer; Estrogen receptor ; Isoforms; Neoadjuvant therapy

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; EXEMESTANE; KI 67 ANTIGEN; LETROZOLE; PROGESTERONE RECEPTOR; ANTHRACYCLINE; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS; AROMATASE INHIBITOR; TAXOID; TUMOR MARKER;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CANCER ADJUVANT THERAPY; CANCER HORMONE THERAPY; CLINICAL EVALUATION; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; HORMONE DETERMINATION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; PREDICTIVE VALIDITY; PREOPERATIVE SYSTEMIC THERAPY; PRIORITY JOURNAL; SYSTEMIC THERAPY; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT CHEMOTHERAPY; BIOPSY; CELL PROLIFERATION; COMPARATIVE STUDY; GERMANY; METABOLISM; PREDICTIVE VALUE; TIME; TISSUE MICROARRAY; TREATMENT OUTCOME;

ANTHRACYCLINES; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; AROMATASE INHIBITORS; BIOPSY; BREAST NEOPLASMS; CELL PROLIFERATION; CHEMOTHERAPY, ADJUVANT; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; GERMANY; HUMANS; IMMUNOHISTOCHEMISTRY; NEOADJUVANT THERAPY; PREDICTIVE VALUE OF TESTS; RECEPTORS, PROGESTERONE; TAXOIDS; TIME FACTORS; TISSUE ARRAY ANALYSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 77956337663     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or-00000904     Document Type: Article

References (58)

1. Skliris GP, Leygue E, Watson PH and Murphy LC: Oestrogen receptor alpha negative breast cancer patients: oestrogen receptor beta as a therapeutic target. J Steroid Biochem Mol Biol 109: 1-10, 2008.
2. Poola I, Abraham J and Baldwin K: Identification of ten exon deleted ERbeta mRNAs in human ovary, breast, uterus and bone tissues: alternate splicing pattern of oestrogen receptor beta mRNA is distinct from that of oestrogen receptor alpha. FEBS Lett 516: 133-138, 2002.
3. Treeck O, Pfeiler G, Horn F, Federhofer B, Houlihan H, Vollmer A and Ortmann O: Novel estrogen receptor beta transcript variants identified in human breast cancer cells affect cell growth and apoptosis of COS-1 cells. Mol Cell Endocrinol 264: 50-60, 2007. (Pubitemid 46097299)
4. Ogawa S, Inoue S, Watanabe T, Orimo A, Hosoi T, Ouchi Y and Muramatsu M: Molecular cloning and characterization of human estrogen receptor betacx: a potential inhibitor of estrogen action in human. Nucleic Acids Res 26: 3505-3512, 1998.
5. Moore JT, McKee DD, Slentz-Kesler K, Moore LB, Jones SA, Horne EL, Su JL, Kliewer SA, Lehmann JM and Willson TM: Cloning and characterization of human oestrogen receptor beta isoforms. Biochem Biophys Res Commun 247: 75-78, 1998. (Pubitemid 28412528)
6. Speirs V, Carder PJ, Lane S, Dodwell D, Lansdown MR and Hanby AM: Oestrogen receptor beta: what it means for patients with breast cancer. Lancet Oncol 5: 174-181, 2004.
7. Mitter D, Ortmann O and Treeck O: Oestrogen receptor beta isoforms - functions and clinical relevance in breast cancer. Zentralbl Gynakol 127: 228-234, 2005.
8. Mandusic V, Nikolic-Vukosavljevic D, Tanic N, Kanjer K, Neskovic-Konstantinovic Z, Celeketic D and Dimitrijevic B: Expression of oestrogen receptor beta wt isoform (ERbeta1) and ERbetaDelta5 splice variant mRNAs in sporadic breast cancer. J Cancer Res Clin Oncol 133: 571-579, 2007. (Pubitemid 46955686)
9. Leung YK, Mak P, Hassan S and Ho SM: Oestrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Proc Natl Acad Sci USA 103: 13162-13167, 2006.
10. Lewandowski S, Kalita K and Kaczmarek L: Oestrogen receptor beta. Potential functional significance of a variety of mRNA isoforms. FEBS Lett 524: 1-5, 2002.
11. Zhao C, Dahlman-Wright K and Gustafsson JA: Oestrogen receptor beta: an overview and update. Nucl Recept Signal 6: E003, 2008.
12. Honma N, Saji S, Kurabayashi R, Aida J, Arai T, Horii R, Akiyama F, Iwase T, Harada N, Younes M, Toi M, Takubo K and Sakamoto G: Oestrogen receptor-beta1 but not oestrogen receptor-betacx is of prognostic value in apocrine carcinoma of the breast. APMIS 116: 923-930, 2008.
13. Skliris GP, Parkes AT, Limer JL, Burdall SE, Carder PJ and Speirs V: Evaluation of seven oestrogen receptor beta antibodies for immunohistochemistry, Western blotting and flow cytometry in human breast tissue. J Pathol 197: 155-162, 2002.
14. Esslimani-Sahla M, Kramar A, Simony-Lafontaine J, Warner M, Gustafsson JA and Rochefort H: Increased oestrogen receptor betacx expression during mammary carcinogenesis. Clin Cancer Res 11: 3170-3174, 2005. (Pubitemid 40637201)
15. Taucher S, Rudas M, Gnant M, Thomanek K, Dubsky P, Roka S, Bachleitner T, Kandioler D, Wenzel C, Steger G, Mittlböck M and Jakesz R: Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 10: 91-98, 2003.
16. Dowsett M, Ebbs SR, Dixon JM, Skene A, Griffith C, Boeddinghaus I, Salter J, Detre S, Hills M, Ashley S, Francis S, Walsh G and Smith IE: Biomarker changes during neoadjuvant anastrozole, tamoxifen or the combination: influence of hormonal status and HER-2 in breast cancer - a study from the IMPACT trialists. J Clin Oncol 23: 2477-2492, 2005.
17. Neubauer H, Gall C, Vogel U, Hornung R, Wallwiener D, Solomayer E and Fehm T: Changes in tumour biological markers during primary systemic chemotherapy (PST). Anticancer Res 28: 1797-1804, 2008. (Pubitemid 351892888)
18. Frassoldati A, Adami F, Banzi C, Criscuolo M, Piccinini L and Silingardi V: Changes of biological features in breast cancer cells determined by primary chemotherapy. Breast Cancer Res Treat 44: 185-192, 1997.
19. Martin MB, Angeloni SV, Garcia-Morales P, Sholler PF, Castro-Galache MD, Ferragut JA and Saceda M: Regulation of oestrogen receptor-alpha expression in MCF-7 cells by taxol. J Endocrinol 180: 487-496, 2004. (Pubitemid 38443400)
20. Burcombe RJ, Makris A, Richman PI, Daley FM, Noble S, Pittam M, Wright D, Allen SA, Dove J and Wilson GD: Evaluation of ER, PR, HER-2 and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 92: 147-155, 2005.
21. Miller WR, Dixon JM, Macfarlane L, Cameron D and Anderson TJ: Pathological features of breast cancer response following neoadjuvant treatment with either letrozole or tamoxifen. Eur J Cancer 39: 462-468, 2003. (Pubitemid 36173690)
22. Miller WR, White S, Dixon JM, Murray J, Renshaw L and Anderson TJ: Proliferation, steroid receptors and clinical/ pathological response in breast cancer treated with letrozole. Br J Cancer 94: 1051-1056, 2006.
23. Rody A, Karn T, Gätje R, Kourtis K, Minckwitz G, Loibl S, Munnes M, Ruckhäberle E, Holtrich U, Kaufmann M and Ahr A: Gene expression profiles of breast cancer obtained from core cut biopsies before neoadjuvant docetaxel, adriamycin and cyclophoshamide chemotherapy correlate with routine prognostic markers and could be used to identify predictive signatures. Zentralbl Gynäkol 128: 76-81, 2006.
24. Rody A, Karn T, Gätje R, Ahr A, Solbach C, Kourtis K, Munnes M, Loibl S, Kissler S, Ruckhäberle E, Holtrich U, von Minckwitz G and Kaufmann M: Gene expression profiling of breast cancer patients treated with docetaxel, doxorubicin, and cyclophosphamide within the GEPARTRIO trial: HER-2, but not topoisomerase II alpha and microtubule-associated protein tau, is highly predictive of tumour response. Breast 16: 86-93, 2007.
25. Zhou B, Yang DQ and Xie F: Biological markers as predictive factors of response to neoadjuvant taxanes and anthracycline chemotherapy in breast carcinoma. Chin Med J (Engl) 121: 387-391, 2008. (Pubitemid 351565982)
26. Wang S, Yang H, Tong F, Zhang J, Yang D, Liu H, Cao Y, Liu P, Zhou P, Cheng L, Liu M and Guo J: Response to neoadjuvant therapy and disease-free survival in patients with triple-negative breast cancer. Gan To Kagaku Ryoho 36: 255-258, 2009.
27. Liedtke C, Mazouni C, Hess KR, André F, Tordai A, Mejia JA, Symmans WF, Gonzalez-Angulo AM, Hennessy B, Green M, Cristofanilli M, Hortobagyi GN and Pusztai L: Response to neoadjuvant therapy and long-term survival in patients with triple-negative breast cancer. J Clin Oncol 26: 1275-1281, 2008.
28. Miller WR, Anderson TJ, Dixon JM and Saunders PT: Oestrogen receptor beta and neoadjuvant therapy with tamoxifen: prediction of response and effects of treatment. Br J Cancer 94: 1333-1338, 2006.
29. Sinn HP, Schmid H, Junkermann H, Huober J, Leppien G, Kaufmann M, Bastert G and Otto HF: Histologic regression of breast cancer after primary (neoadjuvant) chemotherapy. Geburtshilfe Frauenheilkd 54: 552-558, 1994.
30. Remmele W and Stegner HE: Recommendation for uniform definition of an immunoreactive score (IRS) for immunohistochemical oestrogen receptor detection (ER-ICA) in breast cancer tissue. Pathologe 8: 138-140, 1987.
31. Anderson TJ, Dixon JM, Stuart M, Sahmoud T and Miller WR: Effect of neoadjuvant treatment with anastrozole on tumour histology in post-menopausal women with large operable breast cancer. Br J Cancer 87: 334-338, 2002.
32. Skliris GP, Carder PJ, Lansdown MR and Speirs V: Immunohistochemical detection of ERbeta in breast cancer: towards more detailed receptor profiling? Br J Cancer 84: 1095-1098, 2001.
33. Shaaban AM, Green AR, Karthik S, Alizadeh Y, Hughes TA, Harkins L, Ellis IO, Robertson JF, Paish EC, Saunders PT, Groome NP and Speirs V: Nuclear and cytoplasmic expression of ERbeta1, ERbeta2 and ERbeta5 identifies distinct prognostic outcome for breast cancer patients. Clin Cancer Res 14: 5228-5235, 2008.
34. Lazennec G, Bresson D, Lucas A, Chauveau C and Vignon F: ER beta inhibits proliferation and invasion of breast cancer cells. Endocrinology 142: 4120-4130, 2001. (Pubitemid 32802685)
35. Kass L, Erler JT, Dembo M and Weaver VM: Mammary epithelial cell: influence of extracellular matrix composition and organization during development and tumourigenesis. Int J Biochem Cell Biol 39: 1987-1994, 2007.
36. Nelson CM and Bissell MJ: Of extracellular matrix, scaffolds and signaling: tissue architecture regulates development, homeostasis and cancer. Annu Rev Cell Dev Biol 22: 287-309, 2006.
37. Bissell MJ, Kenny PA and Radisky DC: Microenvironmental regulators of tissue structure and function also regulate tumour induction and progression: the role of extracellular matrix and its degrading enzymes. Cold Spring Harb Symp Quant Biol 70: 343-356, 2005.
38. Berrier AL and Yamada KM: Cell-matrix adhesion. J Cell Physiol 213: 565-573, 2007.
39. Neubauer H, Ruoff A, Paessler N, Solomayer E, Wallwiener D and Fehm T: A laminin-rich basement membrane matrix influences oestrogen receptor beta expression and morphology of MDA-MB-231 breast cancer cells. Oncol Rep 21: 475-481, 2009.
40. Omoto Y, Eguchi H, Yamamoto-Yamaguchi Y and Hayashi S: Oestrogen receptor (ER) beta1 and ERbetacx/beta2 inhibit ERalpha function differently in breast cancer cell line MCF7. Oncogene 22: 5011-5020, 2003.
41. Sugiura H, Toyama T, Hara Y, Zhang Z, Kobayashi S, Fujii Y, Iwase H and Yamashita H: Expression of oestrogen receptor beta wild-type and its variant ERbetacx/beta2 is correlated with better prognosis in breast cancer. Jpn J Clin Oncol 37: 820-828, 2007. (Pubitemid 350259000)
42. Schiff PB and Horwitz SB: Taxol stabilizes microtubules in mouse fibroblast cells. Proc Natl Acad Sci USA 77: 1561-1565, 1980.
43. Moos PJ and Fitzpatrick FA: Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc Natl Acad Sci USA 95: 3896-3901, 1998.
44. Stein CA: Mechanisms of action of taxanes in prostate cancer. Semin Oncol 26: 3-7, 1999. (Pubitemid 30000737)
45. Wang LG, Liu XM, Kreis W and Budman DR: The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 44: 355-361, 1999. (Pubitemid 29455579)
46. Speirs V, Skliris GP, Burdall SE and Carder PJ: Distinct expression patterns of ER alpha and ER beta in normal human mammary gland. J Clin Pathol 55: 371-374, 2002. (Pubitemid 34494177)
47. Saunders PT, Millar MR, Williams K, Macpherson S, Harkiss D, Anderson RA, Orr B, Groome NP, Scobie G and Fraser HM: Differential expression of oestrogen receptor-alpha and -beta and androgen receptor in the ovaries of marmosets and humans. Biol Reprod 63: 1098-1105, 2000.
48. Wong NA, Malcomson RD, Jodrell DI, Groome NP, Harrison DJ and Saunders PT: ER beta isoform expression in colorectal carcinoma: an in vivo and in vitro study of clincopathological and molecular correlates. J Pathol 207: 53-60, 2005.
49. Saunders PT, Millar MR, Macpherson S, Irvine DS, Groome NP, Evans LR, Sharpe RM and Scobie GA: ER beta 1 and the ER beta 2 splice variant (ER beta CX/beta 2) are expressed in distinct cell populations in the adult human testes. J Clin Endocrinol Metab 87: 2706-2715, 2002.
50. Critchley HO, Henderson TA, Kelly RW, Scobie GS, Evans LR, Groome NP and Saunders PT: Wild-type oestrogen receptor (ER beta 1) and the splice variant (ERbeta CX/beta 2) are expressed within the human endometrium throughout the normal menstrual cycle. J Clin Endocrinol Metab 87: 5265-5273, 2002.
51. Fehm T, Krawczyk N, Solomayer EF, Becker-Pergola G, Dürr- Störzer S, Neubauer H, Seeger H, Staebler A, Wallwiener D and Becker S: ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients. Breast Cancer Res 10: R76, 2008.
52. Leake R, Barnes D, Pinder S, Ellis I, Anderson L, Anderson T, Adamson R, Rhodes T, Miller K and Walker R: Immunohistochemical detection of steroid receptors in breast cancer: a working protocol. UK Receptor Group, UK NEQAS, The Scottish Breast Cancer Pathology Group, and The Receptor and Biomarker Study Group of the EORTC. J Clin Pathol 53: 634-635, 2000.
53. Mote PA, Johnston JF, Manninen T, Tuohimaa P and Clarke CL: Detection of progesterone receptor forms A and B by immuno-histochemical analysis. J Clin Pathol 54: 624-630, 2001. (Pubitemid 32756446)
54. Blakeman PJ, Hilton P and Bulmer JN: Oestrogen and progesterone receptor expression in the female lower urinary tract, with reference to oestrogen status. BJU Int 86: 32-38, 2000.
55. Scholzen T and Gerdes J: The Ki-67 protein: from the known and the unknown. J Cell Physiol 182: 311-322, 2000.
56. Cattoretti G, Becker MH, Key G, Duchrow M, Schlüter C, Galle J and Gerdes J: Monoclonal antibodies against recombinant parts of the Ki-67 antigen (MIB 1 and MIB 3) detect proliferating cells in microwave-processed formalin-fixed paraffin sections. J Pathol 168: 357-363, 1992. (Pubitemid 23013251)
57. Gerdes J, Becker MH, Key G and Cattoretti G: Immunohistological detection of tumour growth fraction (Ki-67 antigen) in formalin-fixed and routinely processed tissues. J Pathol 168: 85-86, 1992.
58. Lauerova L, Kovarik J, Bartek J, Rejthar A and Vojtesek B: Novel monoclonal antibodies defining epitope of human cyto-keratin 18 molecule. Hybridoma 7: 495-504, 1988.